Home › Funds › Eversept Partners, LP › XENE

Eversept Partners, LP position in XENE

XENON PHARMACEUTICALS INC · Health Care

Eversept Partners, LP reported holding 196,532 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$11.9M, representing 0.62% of its reported portfolio and ranking #41 among its reported holdings. Eversept Partners, LP has disclosed XENE holdings in 4 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)196.53K sh
Reported value held$11.86M
Portfolio Weight0.62%
First reportedQ4 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's XENE position evolved

Eversept Partners, LP first disclosed a stake in XENE in Q4 2024 at 155,540 shares (US$6.1M). The position peaked in Q2 2026 at 196,532 shares, worth US$11.9M. Across 4 filings, Eversept Partners, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 196,532 shares valued at US$11.9M — an increase of 66,958 shares quarter over quarter.. Notable position changes include a 44% trim in Q1 2026 (shares rose 4% over the following quarter), a 52% increase in Q2 2026 (shares fell 38% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 155.54K $6.10M New
Q4 2025 231.38K $10.37M New
Q1 2026 129.57K $7.53M Reduce
Q2 2026 196.53K $11.86M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Eversept Partners, LP held XENE?

Eversept Partners, LP has disclosed XENE holdings in 4 of the last 7 reported quarters, going back to Q4 2024.

What is Eversept Partners, LP's current position in XENE?

As of Q2 2026, Eversept Partners, LP holds 196.53K shares of XENE (XENON PHARMACEUTICALS INC), valued at $11.86M, representing 0.62% of its reported portfolio and ranking #41.

Has Eversept Partners, LP been buying or selling XENE?

In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in XENE. The position peaked in Q2 2026 at 196.53K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.